Get the Stockscreener App
47.31
1.05%
0.49
Rigel Pharmaceuticals stock is traded at $47.31, with a volume of 124.13K.
It is up +1.05% in the last 24 hours and up +6.65% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
See More
Previous Close:
$46.82
Open:
$47.01
24h Volume:
124.13K
Relative Volume:
0.56
Market Cap:
$883.74M
Revenue:
$299.77M
Net Income/Loss:
$364.23M
P/E Ratio:
2.5271
EPS:
18.7211
Net Cash Flow:
$79.27M
1W Performance:
-2.89%
1M Performance:
+6.65%
6M Performance:
+47.57%
1Y Performance:
+68.30%
1-Day Range:
$47.01
$48.52
1-Week Range:
$46.37
$50.49
52-Week Range:
$24.95
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
47.31 | 883.74M | 299.77M | 364.23M | 79.27M | 18.72 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance Australia
Reasons Why Investors Should Consider Betting on Arvinas Stock - Zacks Investment Research
Rigel Pharmaceuticals Inc. Research & Ratings | RI2 - Barron's
Rigel Pharmaceuticals Inc. Research & Ratings | RI2 - Barron's
Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance UK
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
18 new employees at Rigel receive stock awards vesting over four years. - Stock Titan
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate - GlobeNewswire Inc.
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare ConferenceSlideshow (NASDAQ:RIGL) 2026-09-15 - Seeking Alpha
Rigel Pharmaceuticals at Cantor conference: veppanu launch leads growth push - Investing.com Nigeria
Rigel Pharmaceuticals at Cantor conference: veppanu launch leads growth push By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals at Cantor conference: veppanu launch leads growth push - Investing.com Canada
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $85 - Moomoo
Trading the Move, Not the Narrative: (RIGL) Edition - Stock Traders Daily
EVP & Chief Financial Officer At Rigel Pharmaceuticals Exercises Options Worth $123K - Benzinga
Rigel (NASDAQ: RIGL) CCO now holds 61,622 shares - Stock Titan
Rigel Pharmaceuticals (RIGL) CEO returns 2,424 shares to issuer - Stock Titan
Rigel Pharmaceuticals (NASDAQ: RIGL) insider now holds 50,559 shares - Stock Titan
Rigel Pharmaceuticals CFO to present at three m... - Pluang
Rigel to Participate in Upcoming September Investor Conferences - PR Newswire
Rigel Pharmaceuticals Inc. (RIGL) Peer Comparison – Compare with Others - Value Research
Rigel (RIGL) Results Breakdown: EPS Exceeds Its Estimate for the Current Session; Market Reaction: Shares Finish 3.64% Down in Latest TradingSurprise Factor Analysis - Vinanet
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research - MarketBeat
Rigel Pharmaceuticals (RIGL) Institutional Ownership 2026 $RIGL - MarketBeat
HC Wainwright Analysts Increase Earnings Estimates for RIGL - MarketBeat
Rigel Pharmaceuticals Inc (RIGL) (Q2 2026) Earnings Call Highlig - GuruFocus
RIGL Maintains Neutral Rating -- Price Target Raised to $49.00 b - GuruFocus
Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $49 - Moomoo
Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope - Yahoo Finance
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
(RIGL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85 - GuruFocus
Armistice Capital (RIGL) reports 1.67M Rigel Pharmaceuticals shares in 13G/A - Stock Titan
Rigel announces availability of Veppanu in the USA - The Pharma Letter
Rigel Says Breast Cancer Drug Veppanu Now Available in US, Puerto Rico - marketscreener.com
Rigel Pharmaceuticals (RIGL): Soleus Capital group discloses 9.9% ownership stake - Stock Titan
Rigel's VEPPANU Is Now Available for Certain Advanced Breast Cancers - Stock Titan
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer - PR Newswire
Rigel (RIGL) Q2 2026 Earnings Call Transcript - The Globe and Mail
Rigel Pharmaceuticals, Inc. $RIGL Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Janus Henderson Group PLC Boosts Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals Inc (RIGL) Stock News Today - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Issues Pessimistic Estimate for RIGL Earnings - MarketBeat
Pacer Advisors Inc. Purchases 48,882 Shares of Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Cantor Fitzgerald Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $43 - 富途牛牛
HC Wainwright Issues Pessimistic Forecast for RIGL Earnings - MarketBeat
Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts - simplywall.st
Rigel Pharmaceuticals in-licenses Veppanu, targ... - Pluang
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rigel Pharmaceuticals Stock (RIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ali-Jackson Kamil | Director |
Jun 22 '26 |
Sale |
35.00 |
2,500 |
87,500 |
10,125 |
| Ali-Jackson Kamil | Director |
Jun 22 '26 |
Proposed Sale |
35.00 |
2,500 |
87,500 |
0 |
| Schorno Dean L | EVP & Chief Financial Officer |
Jun 01 '26 |
Option Exercise |
14.83 |
3,381 |
50,139 |
79,718 |
| Ali-Jackson Kamil | Director |
May 26 '26 |
Sale |
29.17 |
2,500 |
72,925 |
12,625 |
| Ali-Jackson Kamil | Director |
May 26 '26 |
Proposed Sale |
29.17 |
2,500 |
72,925 |
0 |
| MOOS WALTER H | Director |
Feb 20 '26 |
Option Exercise |
24.00 |
4,000 |
96,000 |
16,722 |
| MOOS WALTER H | Director |
Feb 20 '26 |
Sale |
36.36 |
4,000 |
145,440 |
12,722 |
| MOOS WALTER H | Director |
Feb 20 '26 |
Proposed Sale |
36.36 |
4,000 |
145,440 |
0 |
| RODRIGUEZ RAUL R | CEO, President |
Jan 26 '26 |
Option Exercise |
27.40 |
80,000 |
2,192,000 |
285,243 |
| Schorno Dean L | EVP & Chief Financial Officer |
Dec 22 '25 |
Option Exercise |
21.51 |
6,500 |
139,786 |
64,235 |
4.33%
2.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):